Incidence, prevalence, and antithrombotic management of atrial fibrillation in elderly Germans.

AIMS Data on the epidemiology of atrial fibrillation (AF) and its antithrombotic management in elderly populations are scarce. The aims of this study were to estimate the incidence and prevalence of AF in the elderly in Germany and to describe antithrombotic management of AF cases. METHODS AND RESULTS Estimation of prevalence and incidence was based on data of three German statutory health insurances, which insured more than 800 000 people aged 65 years and older in the study period. The 1-year period prevalence of AF was estimated for each of the years 2004-2007. The incidence rate of AF in 2007 was assessed in patients with a preceding continuous 3-year insurance period without diagnoses of AF. Antithrombotic management of AF was described among incident AF cases in 2008 and predictors for lack of prescriptions of oral anticoagulants were identified. Age-standardized period prevalence of AF among those 65 years or older was 7.7% in 2004, 9.4% in 2005, 9.8% in 2006, and 10.3% in 2007. The age-standardized incidence of AF was 27.4 of 1000 person-years in 2007. Prevalence and incidence increased with age and were higher in men than in women. In 2008, 58.2% of new AF cases received antithrombotic drugs. Treatment was less common among women and older people. CONCLUSION Incidence and prevalence of AF are relatively high in the elderly in Germany. A considerable fraction of new AF cases did not receive antithrombotic drugs in routine care.

[1]  Thomas Wilke,et al.  Incidence and prevalence of atrial fibrillation: an analysis based on 8.3 million patients. , 2013, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[2]  Dietrich Andresen,et al.  Atrial fibrillation management: a prospective survey in ESC member countries: the Euro Heart Survey on Atrial Fibrillation. , 2005, European heart journal.

[3]  P. Wolf,et al.  Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. , 1991, Stroke.

[4]  E. Feuer,et al.  Confidence intervals for directly standardized rates: a method based on the gamma distribution. , 1997, Statistics in medicine.

[5]  G. Breithardt,et al.  The Registry of the German Competence NETwork on Atrial Fibrillation: patient characteristics and initial management , 2008, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[6]  G. Breithardt,et al.  Oral anticoagulation use by patients with atrial fibrillation in Germany , 2012, Thrombosis and Haemostasis.

[7]  R B D'Agostino,et al.  Stroke severity in atrial fibrillation. The Framingham Study. , 1996, Stroke.

[8]  S. Willich,et al.  Anticoagulation treatment for the reduction of stroke in atrial fibrillation: a cohort study to examine the gap between guidelines and routine medical practice , 2007, Journal of Thrombosis and Thrombolysis.

[9]  T. Dawber,et al.  The Framingham Study , 2014 .

[10]  Stephen S. Cha,et al.  Secular Trends in Incidence of Atrial Fibrillation in Olmsted County, Minnesota, 1980 to 2000, and Implications on the Projections for Future Prevalence , 2006, Circulation.

[11]  K. Minematsu,et al.  Atrial fibrillation as a predictive factor for severe stroke and early death in 15 831 patients with acute ischaemic stroke , 2005, Journal of Neurology, Neurosurgery & Psychiatry.

[12]  Jeroen J. Bax,et al.  Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). , 2010, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[13]  Elsayed Z Soliman,et al.  Incidence of atrial fibrillation in whites and African-Americans: the Atherosclerosis Risk in Communities (ARIC) study. , 2009, American heart journal.

[14]  R. Schnabel,et al.  Atrial fibrillation: its prevalence and risk factor profile in the German general population. , 2012, Deutsches Arzteblatt international.

[15]  D. Cook,et al.  Trends in the prevalence of diagnosed atrial fibrillation, its treatment with anticoagulation and predictors of such treatment in UK primary care , 2005, Heart.

[16]  P. Kirchhof,et al.  Management of atrial fibrillation by primary care physicians in Germany: baseline results of the ATRIUM registry , 2011, Clinical Research in Cardiology.

[17]  L E Daly,et al.  Confidence limits made easy: interval estimation using a substitution method. , 1998, American journal of epidemiology.

[18]  L H Kuller,et al.  Incidence of and risk factors for atrial fibrillation in older adults. , 1997, Circulation.

[19]  A. John Camm,et al.  Clinical Relevance of Silent Atrial Fibrillation: Prevalence, Prognosis, Quality of Life, and Management , 2000, Journal of Interventional Cardiac Electrophysiology.

[20]  D. Singer,et al.  Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. , 2001, JAMA.

[21]  E. Williams.  A Classification of Antiarrhythmic Actions Reassessed After a Decade of New Drugs , 1984 .

[22]  E. V. Vaughan Williams.  A classification of antiarrhythmic actions reassessed after a decade of new drugs. , 1984, Journal of clinical pharmacology.

[23]  E. Garbe,et al.  Representativity of dispensations of non-steroidal anti-inflammatory drugs (NSAIDs) in the German Pharmacoepidemiological Research Database , 2010 .

[24]  M. Suling,et al.  Linkage of mother–baby pairs in the German Pharmacoepidemiological Research Database , 2011, Pharmacoepidemiology and drug safety.

[25]  I. Pigeot,et al.  Establishment of a pharmacoepidemiological database in Germany: methodological potential, scientific value and practical limitations , 2008, Pharmacoepidemiology and drug safety.

[26]  M. Smithson.  Statistics with confidence , 2000 .

[27]  G. Breithardt,et al.  Impact of the type of centre on management of AF patients: Surprising evidence for differences in antithrombotic therapy decisions , 2011, Thrombosis and Haemostasis.

[28]  A. Hofman,et al.  Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. , 2006, European heart journal.

[29]  G. Naccarelli,et al.  Increasing prevalence of atrial fibrillation and flutter in the United States. , 2009, The American journal of cardiology.